ARTICLE | Emerging Company Profile
Latest spinout from David Baker’s IPD rescuing failed mAbs by forcing them into cage-like structures for better biodistribution, target engagement
By Karen Tkach Tuzman, Director of Biopharma Intelligence
November 15, 2024 12:02 AM UTC
Archon is packing antibodies into computationally designed geometries to better control their activity, with the goal of addressing well-understood targets failed by free mAbs.
The company, which emerged from stealth Oct. 30 with a $20 million seed round led by Seattle-based Madrona Ventures, is the latest in a long line of spinouts from University of Washington’s Institute for Protein Design (IPD), which is helmed by 2024 Nobel Prize in Chemistry winner David Baker…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654160/archon-tuning-antibodies-through-geometry